avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2015-0-6-28-36avk-470Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESАМИЛОИДОЗ СЕРДЦА У ПОЖИЛЫХAMYLOIDOSIS HEART IN ELDERLYДворецкийЛ. И.DvoretskyL. I.

Москва

Moscow

dvoretski@mail.ruКарповаО. Ю.KarpovaO. Yu.

Москва

Moscow

АлександроваЕ. Н.AlexandrovaE. N.

Москва

Moscow

ПетроваС. Ю.PetrovaS. Yu.

Москва

Moscow

ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical UniversityRussian FederationГоспиталь ветеранов войн № 3 ДЗРоссияHospital for war veterans № 3 The Department of HealthRussian Federation201528122015062836Copyright © Дворецкий Л.И., Карпова О.Ю., Александрова Е.Н., Петрова С.Ю., 20152015Дворецкий Л.И., Карпова О.Ю., Александрова Е.Н., Петрова С.Ю.Dvoretsky L.I., Karpova O.Y., Alexandrova E.N., Petrova S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/470

Приводятся данные о частоте, клинических проявлениях, методах диагностики амилоидоза сердца при различных вариантах амилоидоза. Обсуждаются особенности течения амилоидоза сердца, подчеркиваются трудности диагностики и дифференциальной диагностики у пожилых. В качестве иллюстрации приводится описание клинического случая амилоидоза сердца у 83-летнего больного, основным проявлением которого была сердечная недостаточность.

The data on the incidence, clinical presentation, diagnostic methods amyloidosis of the heart in different types of amyloidosis. The features of the current heart amyloidosis, highlights the difficulty of diagnosis and differential diagnosis in the elderly. As an illustration, describes a clinical case of amyloidosis of the heart in 83-year-old patient, the main manifestation of which was congestive heart failure.

амилоидозАL-амилоидозамилоидоз сердцасердечная недостаточностьamyloidosisAL-amyloidosisamyloidosis of the heartheart failureReferencesRapezzi C., Quarta C.C., Riva L. et al. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat. Rev. Cardiol. 2010; 7: 398–408.Rapezzi C., Quarta C.C., Riva L. et al. Transthyretin-related amyloidoses and the heart: A clinical overview. Nat. Rev. Cardiol. 2010; 7: 398–408.Westermark P., Benson M.D., Buxbaum J.N. et al. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005; 12: 1–4.Westermark P., Benson M.D., Buxbaum J.N. et al. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid. 2005; 12: 1–4.Falk R.H., Dubrey S.W. Amyloid heart disease. Prog. Cardiovasc. Dis. 2010; 52: 347–361.Falk R.H., Dubrey S.W. Amyloid heart disease. Prog. Cardiovasc. Dis. 2010; 52: 347–361.Buxbaum J., Alexander A., Koziol J. et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African-Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am. Heart J. 2010; 159: 864–870.Buxbaum J., Alexander A., Koziol J. et al. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African-Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am. Heart J. 2010; 159: 864–870.Jacobson D., Tagoe C., Schwartzbard A. et al. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am. J. Cardiol. 2011; 108: 440–444.Jacobson D., Tagoe C., Schwartzbard A. et al. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am. J. Cardiol. 2011; 108: 440–444.Gertz M.A., Comenzo R., Falk R.H. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology. 2005; 79: 319–328.Gertz M.A., Comenzo R., Falk R.H. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology. 2005; 79: 319–328.Dubrey, S.W., Hawkins, P.N., Falk, R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011; 97: 75–84.Dubrey, S.W., Hawkins, P.N., Falk, R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011; 97: 75–84.Ng B., Connors L.H., Davidoff R. et al, Senile systemic amyloidosis presenting with heart failure: a comparison with light chainassociated amyloidosis. Archives of Internal Medicine. 2005; 165: 1425–1429.Ng B., Connors L.H., Davidoff R. et al, Senile systemic amyloidosis presenting with heart failure: a comparison with light chainassociated amyloidosis. Archives of Internal Medicine. 2005; 165: 1425–1429.Steiner I. The prevalence of isolated atrial amyloid. The Journal of Pathology. 1987; 153: 395–398.Steiner I. The prevalence of isolated atrial amyloid. The Journal of Pathology. 1987; 153: 395–398.Rocken C., Peters B., Juenemann G. et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002; 106: 2091–2097.Rocken C., Peters B., Juenemann G. et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002; 106: 2091–2097.Goette A., Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent arrhythmogenic substrate?. European Heart Journal. 2004; 25: 1185–1186.Goette A., Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent arrhythmogenic substrate?. European Heart Journal. 2004; 25: 1185–1186.Obici L., Perfetti V., Palladini G. et al, Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta. 2005; 1753: 11–22Obici L., Perfetti V., Palladini G. et al, Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta. 2005; 1753: 11–22Dubrey S.W., Cha K., Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM: Monthly Journal of the Association of Physicians. 1998; 91: 141–157.Dubrey S.W., Cha K., Anderson J. et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM: Monthly Journal of the Association of Physicians. 1998; 91: 141–157.Falk R.H. Diagnosis and management of the cardiac amyloidosis. Circulation. 2005; 112: 2047–2060.Falk R.H. Diagnosis and management of the cardiac amyloidosis. Circulation. 2005; 112: 2047–2060.Tanskanen M., Kiuru-Enari S., Tienari P. et al. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid. 2006; 13: 164–169.Tanskanen M., Kiuru-Enari S., Tienari P. et al. Senile systemic amyloidosis, cerebral amyloid angiopathy, and dementia in a very old Finnish population. Amyloid. 2006; 13: 164–169.Westermark, P., Sletten, K., Johansson, B. et al, Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87: 2843–2845.Westermark, P., Sletten, K., Johansson, B. et al, Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87: 2843–2845.Cornwell, G.G., Murdoch, W.L., Kyle, R.A. et al, Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. American Journal of Medicine. 1983; 75: 618–623.Cornwell, G.G., Murdoch, W.L., Kyle, R.A. et al, Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. American Journal of Medicine. 1983; 75: 618–623.Obici L., Perfetti V., Palladini G. et al. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta. 2005; 1753 (1): 11–22.Obici L., Perfetti V., Palladini G. et al. Clinical aspects of systemic amyloid diseases. Biochim. Biophys. Acta. 2005; 1753 (1): 11–22.Allen L., Doherly C.C. Sudden death in a patient with amyloidosis of the cardiac conduction system. Brit. Heart J. 1984; 51: 233-236.Allen L., Doherly C.C. Sudden death in a patient with amyloidosis of the cardiac conduction system. Brit. Heart J. 1984; 51: 233-236.Сторожаков Г.И. Поражение сердца при амилоидозе. Сердечная Недостаточность. 2008; 9 (5): 250-256.Сторожаков Г.И. Поражение сердца при амилоидозе. Сердечная Недостаточность. 2008; 9 (5): 250-256.Carroll J.D., Gaasch W.H., McAdam K.P. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. The American Journal of Cardiology. 1982; 49: 9–13.Carroll J.D., Gaasch W.H., McAdam K.P. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. The American Journal of Cardiology. 1982; 49: 9–13.Child J.S., Levisman J.A., Abbasi A.S. et al, Echocardiographic manifestations of infiltrative cardiomyopathy — a report of seven cases due to amyloid. Chest. 1976; 70: 726–731.Child J.S., Levisman J.A., Abbasi A.S. et al, Echocardiographic manifestations of infiltrative cardiomyopathy — a report of seven cases due to amyloid. Chest. 1976; 70: 726–731.Bhandari A.K., Nanda N.C. Myocardial texture characterization by two-dimensional echocardiography. The American Journal of Cardiology. 1983; 51: 817–825.Bhandari A.K., Nanda N.C. Myocardial texture characterization by two-dimensional echocardiography. The American Journal of Cardiology. 1983; 51: 817–825.Selvanayagam J.B., Hawkins P.N., Paul B. et al, Evaluation and management of the cardiac amyloidosis. Journal of the American College of Cardiology. 2007; 50: 2101–2110.Selvanayagam J.B., Hawkins P.N., Paul B. et al, Evaluation and management of the cardiac amyloidosis. Journal of the American College of Cardiology. 2007; 50: 2101–2110.Perugini E., Rapezzi C., Piva T. et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006; 92: 343-349.Perugini E., Rapezzi C., Piva T. et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart. 2006; 92: 343-349.Eriksson P., Backman C., Eriksson A. et al, Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Medica Scandinavica. 1987; 221: 39–46.Eriksson P., Backman C., Eriksson A. et al, Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Medica Scandinavica. 1987; 221: 39–46.Perugini E., Guidalotti P.L., Salvi F. et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. Journal of the American College of Cardiology. 2005; 46: 1076–1084.Perugini E., Guidalotti P.L., Salvi F. et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. Journal of the American College of Cardiology. 2005; 46: 1076–1084.Rossi P., Tessonnier L., Frances Y. et al. 99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis. Clinical Nuclear Medicine. 2012; 37: 209–210.Rossi P., Tessonnier L., Frances Y. et al. 99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis. Clinical Nuclear Medicine. 2012; 37: 209–210.de Haro-del Moral F.J., Sánchez-Lajusticia A., Gómez-Bueno M. et al. Role of cardiacscintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype. Revista Espanola de Cardiologia. 2012; 65: 440–446.de Haro-del Moral F.J., Sánchez-Lajusticia A., Gómez-Bueno M. et al. Role of cardiacscintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype. Revista Espanola de Cardiologia. 2012; 65: 440–446.Dharmarajan K., Maurer M.S. Transthyretin Cardiac Amyloidoses in Older North Americans. JAGS. 2012; 60: 765–774.Dharmarajan K., Maurer M.S. Transthyretin Cardiac Amyloidoses in Older North Americans. JAGS. 2012; 60: 765–774.Nishikawa H., Nishiyama, S., Nishimura, S. et al, Echocardiographic findings in nine patients with cardiac amyloidosis: their correlation with necropsy findings. Journal of Cardiology. 1988; 18: 121–133.Nishikawa H., Nishiyama, S., Nishimura, S. et al, Echocardiographic findings in nine patients with cardiac amyloidosis: their correlation with necropsy findings. Journal of Cardiology. 1988; 18: 121–133.Rahman J.E., Helou, E.F., Gelzer-Bell, R. et al, Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. Journal of the American College of Cardiology. 2004; 43: 410–415.Rahman J.E., Helou, E.F., Gelzer-Bell, R. et al, Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. Journal of the American College of Cardiology. 2004; 43: 410–415.

The authors declare that there are no conflicts of interest present.